Literature DB >> 12005388

Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastoma multiforme.

Takanori Kamiryo1, Kenji Tada, Shoji Shiraishi, Naoki Shinojima, Hideo Nakamura, Masato Kochi, Jun-ichi Kuratsu, Hideyuki Saya, Yukitaka Ushio.   

Abstract

OBJECT: One of the most frequent genetic abnormalities found in patients with glioblastoma multiforme (GBM) is homozygous deletion of the p16 tumor suppressor gene. The authors investigated whether this deletion is associated with prognosis in patients with GBM.
METHODS: In 46 adult patients with supratentorial GBM, homozygous deletion of the p16 gene in tumor DNA was examined using the multiplex polymerase chain reaction assay. The deletion was confirmed in 14 (30.4%) of 46 patients, eight (30.8%) of 26 men and six (30.0%) of 20 women. Cox proportional hazard regression analysis, adjusted for age at surgery, the Karnofsky Performance Scale score, extent of resection, and the MIB-1 labeling index. revealed that homozygous deletion of the p16 gene was significantly associated with overall survival and progression-free survival in men, but not in women.
CONCLUSIONS: The results of this study suggest that p16 homozygous deletion is a significant unfavorable prognostic factor in male patients with GBM.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12005388     DOI: 10.3171/jns.2002.96.5.0815

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  16 in total

1.  Intratumoral patterns of clonal evolution in gliomas.

Authors:  Ana Luísa Vital; Maria Dolores Tabernero; Inês Crespo; Olinda Rebelo; Hermínio Tão; Fernando Gomes; Maria Celeste Lopes; Alberto Orfao
Journal:  Neurogenetics       Date:  2009-09-17       Impact factor: 2.660

2.  CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma.

Authors:  M K Sibin; Dhananjaya I Bhat; K V L Narasingarao; Ch Lavanya; G K Chetan
Journal:  Tumour Biol       Date:  2015-04-29

3.  Cytoplasmic, but not nuclear, p16 expression may signal poor prognosis in high-grade astrocytomas.

Authors:  Muhamad Thohar Arifin; Seiji Hama; Yoshinori Kajiwara; Kazuhiko Sugiyama; Taiichi Saito; Shinya Matsuura; Fumiyuki Yamasaki; Kazunori Arita; Kaoru Kurisu
Journal:  J Neurooncol       Date:  2006-04-14       Impact factor: 4.130

4.  Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials.

Authors:  Daniel J Brat; Wendy F Seiferheld; Arie Perry; Elizabeth H Hammond; Kevin J Murray; Alan R Schulsinger; Minesh P Mehta; Walter J Curran
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

Review 5.  Molecular prognostic factors in glioblastoma: state of the art and future challenges.

Authors:  Ana Xavier-Magalhães; Meera Nandhabalan; Chris Jones; Bruno M Costa
Journal:  CNS Oncol       Date:  2013-11

6.  p16(Ink4a) interferes with Abelson virus transformation by enhancing apoptosis.

Authors:  Zohar Sachs; Norman E Sharpless; Ronald A DePinho; Naomi Rosenberg
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

7.  CDKN2A exon-wise deletion status and novel somatic mutations in Indian glioma patients.

Authors:  M K Sibin; Dhananjaya I Bhat; Ch Lavanya; M Jeru Manoj; S Aakershita; G K Chetan
Journal:  Tumour Biol       Date:  2013-09-25

8.  Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas.

Authors:  Stella M Ranuncolo; Mirta Varela; Ana Morandi; José Lastiri; Silvia Christiansen; Elisa Bal de Kier Joffé; María G Pallotta; Lydia Puricelli
Journal:  J Neurooncol       Date:  2004-06       Impact factor: 4.130

9.  Differential expression of p42.3 in low- and high-grade gliomas.

Authors:  Weiqing Wan; Xiaoqing Xu; Guijun Jia; Wenmei Li; Junmei Wang; Tong Ren; Zhen Wu; Junting Zhang; Liwei Zhang; Youyong Lu
Journal:  World J Surg Oncol       Date:  2014-06-14       Impact factor: 2.754

10.  Screening for EGFR amplifications with a novel method and their significance for the outcome of glioblastoma patients.

Authors:  Michał Bieńkowski; Sylwester Piaskowski; Ewelina Stoczyńska-Fidelus; Małgorzata Szybka; Mateusz Banaszczyk; Monika Witusik-Perkowska; Emilia Jesień-Lewandowicz; Dariusz J Jaskólski; Anna Radomiak-Załuska; Dorota Jesionek-Kupnicka; Beata Sikorska; Wielisław Papierz; Piotr Rieske; Paweł P Liberski
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.